An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 207620
Company: NOVARTIS PHARMS CORP

Summary Review

Products on NDA 207620

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
ENTRESTO	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	AB	Yes	No
ENTRESTO	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	AB	Yes	No
ENTRESTO	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 207620

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
07/07/2015	ORIG-1	Approval	Type 1 - New Molecular Entity and Type 4 - New Combination	PRIORITY	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/12/2024	SUPPL-25	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218591Orig1s000;207620Orig1s025ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218591Orig1s000,207620Orig1s025ltr.pdf
10/18/2023	SUPPL-24	Manufacturing (CMC)-Facility	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207620Orig1s024lbl.pdf
02/16/2021	SUPPL-18	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207620Orig1s018ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/207620Orig1s018.pdf
10/01/2019	SUPPL-13	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207620s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/207620Orig1s013ltr.pdf
11/22/2017	SUPPL-8	Labeling-Package Insert, Labeling-Patient Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207620s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207620Orig1s008ltr.pdf
12/21/2016	SUPPL-4	Manufacturing (CMC)		Label is not available on this site.
05/11/2016	SUPPL-2	Manufacturing (CMC)		Label is not available on this site.
02/12/2016	SUPPL-1	Manufacturing (CMC)		Label is not available on this site.

Labels for NDA 207620

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/12/2024	SUPPL-25	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218591Orig1s000;207620Orig1s025ltr.pdf
10/18/2023	SUPPL-24	Manufacturing (CMC)-Facility	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207620Orig1s024lbl.pdf
02/16/2021	SUPPL-18	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf
10/01/2019	SUPPL-13	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207620s013lbl.pdf
11/22/2017	SUPPL-8	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207620s008lbl.pdf
11/22/2017	SUPPL-8	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207620s008lbl.pdf
07/07/2015	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf

Therapeutic Equivalents for NDA 207620

ENTRESTO

TABLET;ORAL; 24MG;26MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
ENTRESTO	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	Yes	AB	207620	NOVARTIS PHARMS CORP
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213682	ALEMBIC
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213680	BIOCON PHARMA
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213605	CRYSTAL
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213676	LAURUS
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213748	MSN
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213604	TORRENT
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	24MG;26MG	TABLET;ORAL	Prescription	No	AB	213719	ZYDUS PHARMS

TABLET;ORAL; 49MG;51MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
ENTRESTO	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	Yes	AB	207620	NOVARTIS PHARMS CORP
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213682	ALEMBIC
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213680	BIOCON PHARMA
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213605	CRYSTAL
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213676	LAURUS
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213748	MSN
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213604	TORRENT
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	49MG;51MG	TABLET;ORAL	Prescription	No	AB	213719	ZYDUS PHARMS

TABLET;ORAL; 97MG;103MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
ENTRESTO	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	Yes	AB	207620	NOVARTIS PHARMS CORP
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213682	ALEMBIC
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213680	BIOCON PHARMA
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213605	CRYSTAL
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213676	LAURUS
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213748	MSN
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213604	TORRENT
SACUBITRIL AND VALSARTAN	SACUBITRIL; VALSARTAN	97MG;103MG	TABLET;ORAL	Prescription	No	AB	213719	ZYDUS PHARMS

Top